Swiss biotechnology company Serono ( SRA) said Monday it agreed to pay $725 million to settle a U.S. government investigation in to its marketing for the drug Serostim. The agreement, which concludes a four-year investigation launched by the U.S. Attorney's Office in Massachusetts, relates to Serono's marketing of a growth hormone used to treat cachexia, or body tissue-wasting, in AIDS patients. The agreement isn't a surprise. In April, Serono said it would take a $725 million charge during the first quarter to cover the Serostim settlement and related costs. "The comprehensive settlements with federal and state agencies will conclude all liabilities to the government in connection with the investigation," said a Serono press release. "We are pleased to put the matter behind us," said Thomas G. Gunning, vice president and general counsel for Serono's U.S. subsidiary, in a prepared statement. "The activities described in the settlement were confined to one unit in our U.S. operations and cover a brief period in our history." Government investigators had asked Serono to produce documents going back to 1992 as they examined the company's marketing practices, including its price-setting related to Medicaid and Medicare programs. Serono's shares were off 36 cents, or 2.2%, to $16.11.